Navigation Links
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
Date:2/11/2008

alating agents and inhibit topoisomerase II, but preclinical data indicate that pixantrone is less toxic to the heart than mitoxantrone and prolonged administration may be possible.

"These results are intriguing, and, like the earlier data in animal models of multiple sclerosis, suggest that pixantrone may be of clinical utility in patients with severe myasthenia gravis or multiple sclerosis. We have been approached by European cooperative groups interested in performing clinical trials in both of these diseases," said Gabriella Pezzoni, Ph.D., Scientific Director of Cell Therapeutics Inc.'s European branch, and one of the investigators in the preclinical study on EAMG.

About the Preclinical Study

In an in vitro rodent model, pixantrone demonstrated a dose-dependent inhibition of T cell responses up to complete suppression of the proliferation in EAMG. EAMG was induced in subject animals using acetylcholine (T-cell) receptor, the autoantigen at the neuromuscular junction. The animals were randomly assigned to four treatment groups -- 1) preventive pixantrone (PIX)group, starting four days after immunization, 2) therapeutic PIX group, starting four weeks after immunization, 3) therapeutic mitoxantrone (MTX) group, starting four weeks after immunization, and 4) vehicle-treated animals as control groups. Doses of both pixantrone and mitoxantrone were equal to one-fourth of LD10 for single i.v. injection in animals. Although both pixantrone and mitoxantrone improved clinical symptoms, reduced weight loss and increased muscle acetylcholine receptor content compared with vehicle-treated rats, pixantrone appeared to be more effective at equitoxic doses.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very acti
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
4. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
5. Newly Approved HIV Drug Shows Great Promise
6. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
7. Research Shows Decas Sweetened Dried Cranberries Pack Twice the Proanthocyanidin Punch as Cranberry Juice Cocktail
8. New Study Shows LEVITRA Successfully Treats Erectile Dysfunction (ED) in Men with Dyslipidemia, Including High Cholesterol
9. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
10. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
11. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
(Date:5/20/2013)...  Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...
Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...
(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...
(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...
(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...
(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...
Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4
... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...
... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...
... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...
... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...
... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...
... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...
Cached Medicine News:Health News:Markel Reports Third Quarter and Nine-Month Results 2Health News:Markel Reports Third Quarter and Nine-Month Results 3Health News:Markel Reports Third Quarter and Nine-Month Results 4Health News:Study Shows Hispanics Prefer Beer 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Healthy bones program reduces hip fractures by 37 percent 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 2Health News:IRIDEX Reports Third Quarter 2008 Financial Results 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 4Health News:IRIDEX Reports Third Quarter 2008 Financial Results 5Health News:IRIDEX Reports Third Quarter 2008 Financial Results 6
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
Medicine Products: